FIT Kit Strategies for Colorectal Cancer Screening
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to improve colorectal cancer screening by testing various methods of delivering a fecal immunochemical test (FIT), which detects blood in the stool. It compares standard and enhanced FIT kits, along with different support methods, such as text messages or phone calls, to assist completion. The goal is to identify the best combination to increase screening rates. The trial seeks residents of Appalachian counties who have had a medical visit in the past two years, are at average risk for colorectal cancer, and are not up-to-date with their screenings. As an unphased trial, this study provides a unique opportunity to contribute to innovative screening methods that could enhance early detection and save lives.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these FIT kit strategies are safe for colorectal cancer screening?
Research shows that fecal immunochemical test (FIT) kits are safe and easy to use for colorectal cancer screening. Studies have found that both enhanced and standard FIT kits effectively detect signs of colorectal cancer with minimal risk. Participants in outreach programs have found the enhanced FIT kit acceptable, while the standard FIT kit remains a reliable choice for home testing. Both kits are noninvasive, avoiding surgery or body entry, which reduces the chance of side effects. No evidence suggests serious problems from using these kits. They are widely recommended for yearly screening in individuals at average risk for colorectal cancer.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it's exploring innovative strategies to boost colorectal cancer screening using FIT kits. Unlike the standard of care, which typically involves a single FIT kit without additional support, this trial is testing enhanced FIT kits alongside personalized patient navigation via text messages or phone calls. This approach could improve screening rates by making it easier for people to complete the tests and follow up on results. By tailoring the support to individual needs, these strategies aim to catch cancer earlier, potentially improving outcomes and saving lives.
What evidence suggests that this trial's strategies could be effective for improving colorectal cancer screening rates?
Studies have shown that fecal immunochemical tests (FIT) effectively detect early-stage colorectal cancer and cost less than more invasive tests. About 60% of patients using FIT at home detected early-stage cancer. In this trial, participants will receive either a standard or enhanced FIT kit. Research indicates that both standard and enhanced FIT kits effectively screen for colorectal cancer. The enhanced FIT kit includes extra features to aid in cancer detection, but both types are strong at detecting it. While ongoing research aims to understand the long-term effects on survival rates, FIT kits are generally considered a reliable screening tool.56789
Who Is on the Research Team?
Paul Reiter, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals in Appalachia who are due for colorectal cancer screening. It's not specified who can't join, but typically those with a recent colonoscopy or health issues affecting the test might be excluded.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive a FIT kit and patient navigation via telephone or text message
Follow-up
Participants are monitored for the return of the completed FIT kit
What Are the Treatments Tested in This Trial?
Interventions
- Enhanced FIT kit
- Standard FIT kit
- Telephone patient navigation
- Text message patient navigation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator